Found 50 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135944
(US8859586, 28)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)CC(C)C)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;9.34,-8.47,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H42ClNO4/c1-19(2)18-31(5,35)23-9-13-25(14-10-23)33-29(34)16-22-15-27(36-6)28(37-20(3)4)17-26(22)30(33)21-7-11-24(32)12-8-21/h7-8,11-12,15,17,19-20,23,25,30,35H,9-10,13-14,16,18H2,1-6H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135945
(US8859586, 30)Show SMILES CCCCC(C)(O)C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O |(14.67,-5.39,;13.34,-6.16,;12,-5.39,;10.67,-6.16,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;8,-4.62,;8,-3.08,;6.67,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,)| Show InChI InChI=1S/C31H42ClNO4/c1-6-7-16-31(4,35)23-10-14-25(15-11-23)33-29(34)18-22-17-27(36-5)28(37-20(2)3)19-26(22)30(33)21-8-12-24(32)13-9-21/h8-9,12-13,17,19-20,23,25,30,35H,6-7,10-11,14-16,18H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135946
(US8859586, 31)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)CCC(C)C)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;12,-5.39,;13.34,-6.16,;14.67,-5.39,;13.34,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H44ClNO4/c1-20(2)15-16-32(5,36)24-9-13-26(14-10-24)34-30(35)18-23-17-28(37-6)29(38-21(3)4)19-27(23)31(34)22-7-11-25(33)12-8-22/h7-8,11-12,17,19-21,24,26,31,36H,9-10,13-16,18H2,1-6H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 7 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM30628
(US8859586, 29)Show SMILES CCCC(C)(O)C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O |(12,-8.47,;10.67,-7.7,;10.67,-6.16,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;8,-4.62,;8,-3.08,;6.67,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,)| Show InChI InChI=1S/C17H15NO7S2/c1-10(19)18(11-4-6-13-15(8-11)26-17(20)25-13)27(21,22)16-9-12(23-2)5-7-14(16)24-3/h4-9H,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 7.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135938
(US8859586, 22)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)[C@@](C)(O)C3CCOCC3)[C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wU:15.18,24.26,wD:15.17,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H42ClNO5/c1-20(2)39-29-19-27-22(17-28(29)37-4)18-30(35)34(31(27)21-5-9-25(33)10-6-21)26-11-7-23(8-12-26)32(3,36)24-13-15-38-16-14-24/h5-6,9-10,17,19-20,23-24,26,31,36H,7-8,11-16,18H2,1-4H3/t23?,26?,31-,32+/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 12.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135947
(US8859586, 32)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)c3ccoc3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;12.08,-5.53,;13.11,-6.68,;12.34,-8.01,;10.83,-7.69,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H36ClNO5/c1-19(2)38-28-17-26-21(15-27(28)36-4)16-29(34)33(30(26)20-5-9-24(32)10-6-20)25-11-7-22(8-12-25)31(3,35)23-13-14-37-18-23/h5-6,9-10,13-15,17-19,22,25,30,35H,7-8,11-12,16H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 27.6 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135937
(US8859586, 21)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H42ClNO5/c1-20(2)39-29-19-27-22(17-28(29)37-4)18-30(35)34(31(27)21-5-9-25(33)10-6-21)26-11-7-23(8-12-26)32(3,36)24-13-15-38-16-14-24/h5-6,9-10,17,19-20,23-24,26,31,36H,7-8,11-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 36 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135932
(US8859586, 16)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(C)O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-6.16,;8.57,-6.72,;10.11,-4.06,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H36ClNO4/c1-17(2)34-25-16-23-19(14-24(25)33-5)15-26(31)30(27(23)18-6-10-21(29)11-7-18)22-12-8-20(9-13-22)28(3,4)32/h6-7,10-11,14,16-17,20,22,27,32H,8-9,12-13,15H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135942
(US8859586, 26)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)c3cccc(F)c3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;14.67,-5.39,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C33H37ClFNO4/c1-20(2)40-30-19-28-22(16-29(30)39-4)17-31(37)36(32(28)21-8-12-25(34)13-9-21)27-14-10-23(11-15-27)33(3,38)24-6-5-7-26(35)18-24/h5-9,12-13,16,18-20,23,27,32,38H,10-11,14-15,17H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 61 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135940
(US8859586, 24)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(O)c3cccc(F)c3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;12,-10.01,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H35ClFNO4/c1-19(2)39-29-18-27-23(16-28(29)38-3)17-30(36)35(31(27)20-7-11-24(33)12-8-20)26-13-9-21(10-14-26)32(37)22-5-4-6-25(34)15-22/h4-8,11-12,15-16,18-19,21,26,31-32,37H,9-10,13-14,17H2,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 72 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135926
(US8859586, 10)Show SMILES CCCN(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)C(C)=O |(13.34,-4.62,;12,-5.39,;10.67,-4.62,;9.34,-5.39,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;9.34,-6.93,;10.67,-7.7,;8,-7.7,)| Show InChI InChI=1S/C30H39ClN2O4/c1-6-15-32(20(4)34)24-11-13-25(14-12-24)33-29(35)17-22-16-27(36-5)28(37-19(2)3)18-26(22)30(33)21-7-9-23(31)10-8-21/h7-10,16,18-19,24-25,30H,6,11-15,17H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 79 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135933
(US8859586, 17)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;12,-5.39,;13.34,-4.62,;13.34,-3.08,;12,-2.31,;10.67,-3.08,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H40ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30-31,35H,6-7,10-15,17H2,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 106 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135939
(US8859586, 23)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)[C@](C)(O)C3CCOCC3)[C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wU:15.17,24.26,wD:15.18,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H42ClNO5/c1-20(2)39-29-19-27-22(17-28(29)37-4)18-30(35)34(31(27)21-5-9-25(33)10-6-21)26-11-7-23(8-12-26)32(3,36)24-13-15-38-16-14-24/h5-6,9-10,17,19-20,23-24,26,31,36H,7-8,11-16,18H2,1-4H3/t23?,26?,31-,32-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135919
(US8859586, 3)Show SMILES CCN(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)C(C)=O |(8,-7.7,;9.34,-6.93,;9.34,-5.39,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;10.67,-4.62,;12,-5.39,;10.67,-3.08,)| Show InChI InChI=1S/C29H37ClN2O4/c1-6-31(19(4)33)23-11-13-24(14-12-23)32-28(34)16-21-15-26(35-5)27(36-18(2)3)17-25(21)29(32)20-7-9-22(30)10-8-20/h7-10,15,17-18,23-24,29H,6,11-14,16H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 183 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135927
(US8859586, 11)Show SMILES CCCN(C=O)C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O |(13.34,-4.62,;12,-5.39,;10.67,-4.62,;9.34,-5.39,;9.34,-6.93,;8,-7.7,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,)| Show InChI InChI=1S/C29H37ClN2O4/c1-5-14-31(18-33)23-10-12-24(13-11-23)32-28(34)16-21-15-26(35-4)27(36-19(2)3)17-25(21)29(32)20-6-8-22(30)9-7-20/h6-9,15,17-19,23-24,29H,5,10-14,16H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 189 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135928
(US8859586, 12)Show SMILES CCCCN(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)C(C)=O |(13.39,7.49,;12.62,6.16,;11.08,6.16,;10.31,4.83,;8.77,4.83,;8,3.49,;8.77,2.16,;8,.83,;6.46,.83,;5.69,2.16,;6.46,3.49,;5.69,-.51,;6.46,-1.84,;8,-1.84,;8.77,-.51,;10.31,-.51,;11.08,-1.84,;12.62,-1.84,;10.31,-3.18,;8.77,-3.18,;5.69,-3.18,;6.46,-4.51,;5.69,-5.84,;6.46,-7.18,;8,-7.18,;8.77,-5.84,;8.77,-8.51,;4.15,-5.84,;3.38,-7.18,;4.15,-8.51,;3.38,-4.51,;4.15,-3.18,;3.38,-1.84,;4.15,-.51,;3.38,.83,;8,6.16,;6.46,6.16,;8.77,7.49,)| Show InChI InChI=1S/C31H41ClN2O4/c1-6-7-16-33(21(4)35)25-12-14-26(15-13-25)34-30(36)18-23-17-28(37-5)29(38-20(2)3)19-27(23)31(34)22-8-10-24(32)11-9-22/h8-11,17,19-20,25-26,31H,6-7,12-16,18H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 257 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135943
(US8859586, 27)Show SMILES CCC(O)(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)c1cccc(F)c1 |(7.03,-6.72,;8.57,-6.72,;9.34,-5.39,;10.11,-4.06,;8,-4.62,;8,-3.08,;6.67,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;14.67,-5.39,;12,-5.39,)| Show InChI InChI=1S/C34H39ClFNO4/c1-5-34(39,25-7-6-8-27(36)19-25)24-11-15-28(16-12-24)37-32(38)18-23-17-30(40-4)31(41-21(2)3)20-29(23)33(37)22-9-13-26(35)14-10-22/h6-10,13-14,17,19-21,24,28,33,39H,5,11-12,15-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 266 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135923
(US8859586, 7)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)C(N)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;10.67,-3.08,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H34ClN3O4/c1-16(2)35-24-15-22-18(13-23(24)34-4)14-25(32)31(26(22)17-5-7-19(28)8-6-17)21-11-9-20(10-12-21)30(3)27(29)33/h5-8,13,15-16,20-21,26H,9-12,14H2,1-4H3,(H2,29,33) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 372 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135935
(US8859586, 19)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)[C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wU:23.25,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3/t21?,25?,30-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 386 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135918
(US8859586, 2)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;12,-5.39,;10.67,-3.08,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H35ClN2O4/c1-17(2)35-26-16-24-20(14-25(26)34-5)15-27(33)31(28(24)19-6-8-21(29)9-7-19)23-12-10-22(11-13-23)30(4)18(3)32/h6-9,14,16-17,22-23,28H,10-13,15H2,1-5H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 386 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135925
(US8859586, 9)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)C(=O)CCO)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;10.67,-3.08,;12,-5.39,;13.34,-4.62,;14.67,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C29H37ClN2O5/c1-18(2)37-26-17-24-20(15-25(26)36-4)16-28(35)32(29(24)19-5-7-21(30)8-6-19)23-11-9-22(10-12-23)31(3)27(34)13-14-33/h5-8,15,17-18,22-23,29,33H,9-14,16H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 406 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135941
(US8859586, 25)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)c3cccc(F)c3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;12,-10.01,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H33ClFNO4/c1-19(2)39-29-18-27-23(16-28(29)38-3)17-30(36)35(31(27)20-7-11-24(33)12-8-20)26-13-9-21(10-14-26)32(37)22-5-4-6-25(34)15-22/h4-8,11-12,15-16,18-19,21,26,31H,9-10,13-14,17H2,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 531 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135929
(US8859586, 13)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C3CCOCC3)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;10.67,-4.62,;12,-5.39,;13.34,-4.62,;13.34,-3.08,;12,-2.31,;10.67,-3.08,;9.34,-6.93,;10.67,-7.7,;8,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H41ClN2O5/c1-20(2)40-30-19-28-23(17-29(30)38-4)18-31(37)35(32(28)22-5-7-24(33)8-6-22)26-11-9-25(10-12-26)34(21(3)36)27-13-15-39-16-14-27/h5-8,17,19-20,25-27,32H,9-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 602 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135934
(US8859586, 18)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 610 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135924
(US8859586, 8)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N3CCNC3=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;9.5,-6.92,;11,-7.24,;11.77,-5.91,;10.74,-4.76,;11.06,-3.26,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H34ClN3O4/c1-17(2)36-25-16-23-19(14-24(25)35-3)15-26(33)32(27(23)18-4-6-20(29)7-5-18)22-10-8-21(9-11-22)31-13-12-30-28(31)34/h4-7,14,16-17,21-22,27H,8-13,15H2,1-3H3,(H,30,34) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 681 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135930
(US8859586, 14)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(CCCO)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(.87,15.85,;2.41,15.85,;3.18,14.52,;4.72,14.52,;5.49,13.19,;7.03,13.19,;7.8,11.85,;9.34,11.85,;7.03,10.52,;7.8,9.18,;7.03,7.85,;7.8,6.52,;9.34,6.52,;10.11,7.85,;9.34,9.18,;10.11,5.18,;11.65,5.18,;12.42,3.85,;13.96,3.85,;14.73,2.52,;9.34,3.85,;10.11,2.52,;7.8,3.85,;5.49,10.52,;4.72,9.18,;5.49,7.85,;4.72,6.52,;3.18,6.52,;2.41,5.18,;2.41,7.85,;3.18,9.18,;4.72,11.85,;3.18,11.85,;2.41,13.19,;.87,13.19,;.1,11.85,;.87,10.52,;-1.44,11.85,)| Show InChI InChI=1S/C30H39ClN2O5/c1-19(2)38-28-18-26-22(16-27(28)37-4)17-29(36)33(30(26)21-6-8-23(31)9-7-21)25-12-10-24(11-13-25)32(20(3)35)14-5-15-34/h6-9,16,18-19,24-25,30,34H,5,10-15,17H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 720 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135917
(US8859586, 1)Show SMILES COc1cc2CC(=O)N(C3CCCCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C Show InChI InChI=1S/C25H30ClNO3/c1-16(2)30-23-15-21-18(13-22(23)29-3)14-24(28)27(20-7-5-4-6-8-20)25(21)17-9-11-19(26)12-10-17/h9-13,15-16,20,25H,4-8,14H2,1-3H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 894 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135920
(US8859586, 4)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)NC(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;10.67,-4.62,;12,-5.39,;10.67,-3.08,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H33ClN2O4/c1-16(2)34-25-15-23-19(13-24(25)33-4)14-26(32)30(27(23)18-5-7-20(28)8-6-18)22-11-9-21(10-12-22)29-17(3)31/h5-8,13,15-16,21-22,27H,9-12,14H2,1-4H3,(H,29,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 969 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135931
(US8859586, 15)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H32ClNO4/c1-16(2)33-25-15-23-20(13-24(25)32-4)14-26(31)29(22-11-7-18(8-12-22)17(3)30)27(23)19-5-9-21(28)10-6-19/h5-6,9-10,13,15-16,18,22,27H,7-8,11-12,14H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 993 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135922
(US8859586, 6)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)NC(N)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;10.67,-4.62,;10.67,-3.08,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C26H32ClN3O4/c1-15(2)34-23-14-21-17(12-22(23)33-3)13-24(31)30(25(21)16-4-6-18(27)7-5-16)20-10-8-19(9-11-20)29-26(28)32/h4-7,12,14-15,19-20,25H,8-11,13H2,1-3H3,(H3,28,29,32) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.41E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135936
(US8859586, 20)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)[C@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wD:23.25,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3/t21?,25?,30-/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.55E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
E3 ubiquitin-protein ligase Mdm2
(Homo sapiens (Human)) | BDBM135921
(US8859586, 5)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)CCO)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;12,-5.39,;13.34,-4.62,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H37ClN2O4/c1-18(2)35-26-17-24-20(15-25(26)34-4)16-27(33)31(28(24)19-5-7-21(29)8-6-19)23-11-9-22(10-12-23)30(3)13-14-32/h5-8,15,17-18,22-23,28,32H,9-14,16H2,1-4H3 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.43E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135945
(US8859586, 30)Show SMILES CCCCC(C)(O)C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O |(14.67,-5.39,;13.34,-6.16,;12,-5.39,;10.67,-6.16,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;8,-4.62,;8,-3.08,;6.67,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,)| Show InChI InChI=1S/C31H42ClNO4/c1-6-7-16-31(4,35)23-10-14-25(15-11-23)33-29(34)18-22-17-27(36-5)28(37-20(2)3)19-26(22)30(33)21-8-12-24(32)13-9-21/h8-9,12-13,17,19-20,23,25,30,35H,6-7,10-11,14-16,18H2,1-5H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.38E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135932
(US8859586, 16)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(C)O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-6.16,;8.57,-6.72,;10.11,-4.06,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H36ClNO4/c1-17(2)34-25-16-23-19(14-24(25)33-5)15-26(31)30(27(23)18-6-10-21(29)11-7-18)22-12-8-20(9-13-22)28(3,4)32/h6-7,10-11,14,16-17,20,22,27,32H,8-9,12-13,15H2,1-5H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.78E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135924
(US8859586, 8)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N3CCNC3=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;9.5,-6.92,;11,-7.24,;11.77,-5.91,;10.74,-4.76,;11.06,-3.26,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C28H34ClN3O4/c1-17(2)36-25-16-23-19(14-24(25)35-3)15-26(33)32(27(23)18-4-6-20(29)7-5-18)22-10-8-21(9-11-22)31-13-12-30-28(31)34/h4-7,14,16-17,21-22,27H,8-13,15H2,1-3H3,(H,30,34) | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.16E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135937
(US8859586, 21)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)(O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;8.57,-6.72,;10.11,-4.06,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H42ClNO5/c1-20(2)39-29-19-27-22(17-28(29)37-4)18-30(35)34(31(27)21-5-9-25(33)10-6-21)26-11-7-23(8-12-26)32(3,36)24-13-15-38-16-14-24/h5-6,9-10,17,19-20,23-24,26,31,36H,7-8,11-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.98E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135933
(US8859586, 17)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;12,-5.39,;13.34,-4.62,;13.34,-3.08,;12,-2.31,;10.67,-3.08,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H40ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30-31,35H,6-7,10-15,17H2,1-3H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.04E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135936
(US8859586, 20)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)[C@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wD:23.25,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3/t21?,25?,30-/m1/s1 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 3.48E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135935
(US8859586, 19)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)[C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C |wU:23.25,(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3/t21?,25?,30-/m0/s1 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.25E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135926
(US8859586, 10)Show SMILES CCCN(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)C(C)=O |(13.34,-4.62,;12,-5.39,;10.67,-4.62,;9.34,-5.39,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;9.34,-6.93,;10.67,-7.7,;8,-7.7,)| Show InChI InChI=1S/C30H39ClN2O4/c1-6-15-32(20(4)34)24-11-13-25(14-12-24)33-29(35)17-22-16-27(36-5)28(37-19(2)3)18-26(22)30(33)21-7-9-23(31)10-8-21/h7-10,16,18-19,24-25,30H,6,11-15,17H2,1-5H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.31E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135917
(US8859586, 1)Show SMILES COc1cc2CC(=O)N(C3CCCCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C Show InChI InChI=1S/C25H30ClNO3/c1-16(2)30-23-15-21-18(13-22(23)29-3)14-24(28)27(20-7-5-4-6-8-20)25(21)17-9-11-19(26)12-10-17/h9-13,15-16,20,25H,4-8,14H2,1-3H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.43E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135940
(US8859586, 24)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(O)c3cccc(F)c3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;12,-10.01,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H35ClFNO4/c1-19(2)39-29-18-27-23(16-28(29)38-3)17-30(36)35(31(27)20-7-11-24(33)12-8-20)26-13-9-21(10-14-26)32(37)22-5-4-6-25(34)15-22/h4-8,11-12,15-16,18-19,21,26,31-32,37H,9-10,13-14,17H2,1-3H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.89E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135934
(US8859586, 18)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(=O)C3CCOCC3)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;8,-7.7,;8,-9.24,;9.34,-10.01,;10.67,-9.24,;10.67,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C31H38ClNO5/c1-19(2)38-28-18-26-23(16-27(28)36-3)17-29(34)33(30(26)20-4-8-24(32)9-5-20)25-10-6-21(7-11-25)31(35)22-12-14-37-15-13-22/h4-5,8-9,16,18-19,21-22,25,30H,6-7,10-15,17H2,1-3H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 5.99E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135943
(US8859586, 27)Show SMILES CCC(O)(C1CCC(CC1)N1C(c2ccc(Cl)cc2)c2cc(OC(C)C)c(OC)cc2CC1=O)c1cccc(F)c1 |(7.03,-6.72,;8.57,-6.72,;9.34,-5.39,;10.11,-4.06,;8,-4.62,;8,-3.08,;6.67,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;4,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,;-1.33,-.77,;-2.67,,;-4,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;10.67,-6.16,;10.67,-7.7,;12,-8.47,;13.34,-7.7,;13.34,-6.16,;14.67,-5.39,;12,-5.39,)| Show InChI InChI=1S/C34H39ClFNO4/c1-5-34(39,25-7-6-8-27(36)19-25)24-11-15-28(16-12-24)37-32(38)18-23-17-30(40-4)31(41-21(2)3)20-29(23)33(37)22-9-13-26(35)14-10-22/h6-10,13-14,17,19-21,24,28,33,39H,5,11-12,15-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.34E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135929
(US8859586, 13)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C3CCOCC3)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;10.67,-4.62,;12,-5.39,;13.34,-4.62,;13.34,-3.08,;12,-2.31,;10.67,-3.08,;9.34,-6.93,;10.67,-7.7,;8,-7.7,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C32H41ClN2O5/c1-20(2)40-30-19-28-23(17-29(30)38-4)18-31(37)35(32(28)22-5-7-24(33)8-6-22)26-11-9-25(10-12-26)34(21(3)36)27-13-15-39-16-14-27/h5-8,17,19-20,25-27,32H,9-16,18H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.51E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135923
(US8859586, 7)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)C(N)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;10.67,-3.08,;12,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H34ClN3O4/c1-16(2)35-24-15-22-18(13-23(24)34-4)14-25(32)31(26(22)17-5-7-19(28)8-6-17)21-11-9-20(10-12-21)30(3)27(29)33/h5-8,13,15-16,20-21,26H,9-12,14H2,1-4H3,(H2,29,33) | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 6.57E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135931
(US8859586, 15)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;8,-4.62,;6.67,-5.39,;5.33,-4.62,;9.34,-5.39,;10.67,-4.62,;9.34,-6.93,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H32ClNO4/c1-16(2)33-25-15-23-20(13-24(25)32-4)14-26(31)29(22-11-7-18(8-12-22)17(3)30)27(23)19-5-9-21(28)10-6-19/h5-6,9-10,13,15-16,18,22,27H,7-8,11-12,14H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 7.61E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135930
(US8859586, 14)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(CCCO)C(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(.87,15.85,;2.41,15.85,;3.18,14.52,;4.72,14.52,;5.49,13.19,;7.03,13.19,;7.8,11.85,;9.34,11.85,;7.03,10.52,;7.8,9.18,;7.03,7.85,;7.8,6.52,;9.34,6.52,;10.11,7.85,;9.34,9.18,;10.11,5.18,;11.65,5.18,;12.42,3.85,;13.96,3.85,;14.73,2.52,;9.34,3.85,;10.11,2.52,;7.8,3.85,;5.49,10.52,;4.72,9.18,;5.49,7.85,;4.72,6.52,;3.18,6.52,;2.41,5.18,;2.41,7.85,;3.18,9.18,;4.72,11.85,;3.18,11.85,;2.41,13.19,;.87,13.19,;.1,11.85,;.87,10.52,;-1.44,11.85,)| Show InChI InChI=1S/C30H39ClN2O5/c1-19(2)38-28-18-26-22(16-27(28)37-4)17-29(36)33(30(26)21-6-8-23(31)9-7-21)25-12-10-24(11-13-25)32(20(3)35)14-5-15-34/h6-9,16,18-19,24-25,30,34H,5,10-15,17H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 8.51E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135925
(US8859586, 9)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)N(C)C(=O)CCO)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;9.34,-6.93,;10.67,-4.62,;10.67,-3.08,;12,-5.39,;13.34,-4.62,;14.67,-5.39,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C29H37ClN2O5/c1-18(2)37-26-17-24-20(15-25(26)36-4)16-28(35)32(29(24)19-5-7-21(30)8-6-19)23-11-9-22(10-12-23)31(3)27(34)13-14-33/h5-8,15,17-18,22-23,29,33H,9-14,16H2,1-4H3 | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 9.21E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Protein Mdm4
(Homo sapiens (Human)) | BDBM135920
(US8859586, 4)Show SMILES COc1cc2CC(=O)N(C3CCC(CC3)NC(C)=O)C(c3ccc(Cl)cc3)c2cc1OC(C)C |(-4,-.77,;-2.67,,;-1.33,-.77,;;1.33,-.77,;2.67,,;4,-.77,;5.33,,;4,-2.31,;5.33,-3.08,;5.33,-4.62,;6.67,-5.39,;8,-4.62,;8,-3.08,;6.67,-2.31,;9.34,-5.39,;10.67,-4.62,;12,-5.39,;10.67,-3.08,;2.67,-3.08,;2.67,-4.62,;4,-5.39,;4,-6.93,;2.67,-7.7,;2.67,-9.24,;1.33,-6.93,;1.33,-5.39,;1.33,-2.31,;,-3.08,;-1.33,-2.31,;-2.67,-3.08,;-2.67,-4.62,;-1.33,-5.39,;-4,-5.39,)| Show InChI InChI=1S/C27H33ClN2O4/c1-16(2)34-25-15-23-19(13-24(25)33-4)14-26(32)30(27(23)18-5-7-20(28)8-6-18)22-11-9-21(10-12-22)29-17(3)31/h5-8,13,15-16,21-22,27H,9-12,14H2,1-4H3,(H,29,31) | PDB
MMDB
NCI pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 9.52E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The inhibition of p53-MDM2 and p53-MDM4 interactions is measured by time resolved fluorescence energy transfer (TR-FRET). Fluorescence energy transfe... |
US Patent US8859586 (2014)
BindingDB Entry DOI: 10.7270/Q2RF5SR6 |
More data for this
Ligand-Target Pair | |
Search and Browse
